(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Doctor's orders? ‘Belly laugh at least two to five days a week' - 2Track down Your Optimal Conservative Vehicle: Famous Brands to Consider
- 323 Most Amusing Messages At any point Sent Among Youngsters and Their Folks
- 419 Strange Motion pictures You Shouldn't Watch With Your Mum
- 5FDA updates risk classification for voluntary shredded cheese recall
- At least 30 killed in attack on Nigeria village
- Current Chateaus: Advancement and Style
- Dutch police probe a small blast outside a pro-Israel Christian center
- Far-right AfD invited back to Munich Security Conference in 2026
- 13 must-see moon events in 2026: Eclipses, supermoons, conjunctions and more
- These four astronauts could soon travel farther from Earth than anyone has gone before
- The Best Games Crossroads in History
- China resumes flights to North Korea after a six-year pause
- The Development of Shipping: Controlling Towards a More Associated Future
